Health insurer to stop covering uterine procedure

Highmark Inc., which sells plans in Pennsylvania, Delaware and West Virginia, will stop covering power morcellation, a technique often used in hysterectomies, after the Food and Drug Administration advised doctors against it because it may spread cancer. 

The Wall Street Journal: Health Insurer To Stop Covering Uterine Procedure
In the procedure, a bladed device is used to cut up common uterine masses called fibroids, often in hysterectomies, so the tissue can be removed through tiny incisions in minimally invasive surgery. Highmark is the first insurer known to be halting coverage of power morcellation, and the move is the latest in a series of mounting pressures on use of the tool. ... The FDA estimates the instruments were being used in 50,000 hysterectomies a year (Levitz, 8/2).

Reuters: U.S. Insurer To Stop Coverage Of Gynecological Procedure
A health insurer with 5.2 million members in three Eastern U.S. states said on Saturday it would stop providing coverage for a procedure called laparoscopic power morcellation that is used in gynecological surgery and may inadvertently spread cancer. Highmark Inc, which has customers in Pennsylvania, Delaware and West Virginia, will stop covering the procedure on Sept. 1, company spokesman Aaron Billger said in an email. It is the first insurer to halt coverage of power morcellation after the U.S. Food and Drug Administration advised doctors in April against it (Walsh, 8/3).

http://www.kaiserhealthnews.orgThis article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Healthcare News

Tags: , ,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Women with a medical history of breast or ovarian cancer often fail to test for inherited genetic changes